IPHA:NSD-Innate Pharma (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.19

Change

0.00 (0.00)%

Market Cap

N/A

Volume

8.12K

Analyst Target

USD 11.98
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 65.38B
ARGX argenx NV ADR

N/A

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 32.75B
ONC BeiGene, Ltd.

N/A

USD 27.70B
RPRX Royalty Pharma Plc

N/A

USD 18.35B
SMMT Summit Therapeutics PLC

N/A

USD 13.53B
INSM Insmed Inc

N/A

USD 11.84B
INCY Incyte Corporation

N/A

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 11.29B

ETFs Containing IPHA

CNCR Loncar Cancer Immunothera.. 1.77 % 0.79 %

N/A

USD 6.95M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.02% 82% B 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.02% 82% B 86% B+
Trailing 12 Months  
Capital Gain -20.07% 63% D 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.07% 63% D 35% F
Trailing 5 Years  
Capital Gain -65.40% 55% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.40% 55% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain -15.27% 31% F 19% F
Dividend Return -15.27% 31% F 19% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.83% 91% A- 66% D+
Risk Adjusted Return -59.14% 21% F 13% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector